Human IL-28A/IFN-lambda 2 Antibody

Catalog #: MAB1587
3 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB1587
MAB1587-SP

IL‑28A/IFN‑ lambda 2 Inhibition of EMCV‑induced Cytopathy and Neutralization by Human IL‑28A/IFN‑ lambda 2 Antibody.

1 Image

Product Details

Citations (3)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human IL-28A/IFN-lambda 2 Antibody Summary

Species Reactivity

Human

Specificity

Detects human IL‑28A/IFN‑ lambda 2 in direct ELISAs. In direct ELISAs, 83% cross-reactivity with recombinant human (rh) IL-28B/IFN-lambda 3 and no cross-reactivity with recombinant mouse IL-28B/IFN-lambda 3 or rhIL-29/IFN-l1 is observed.

Source

Monoclonal Mouse IgG₁ Clone # 248526

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant human IL‑28A/IFN‑ lambda 2
Val26-Val200
Accession # Q8IZJ0

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Neutralization

Measured by its ability to neutralize IL‑28A/IFN‑ lambda 2 inhibition of EMCV-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The Neutralization Dose (ND₅₀) is typically 1-8 µg/mL in the presence of 0.1 µg/mL Recombinant Human IL‑28A/IFN‑ lambda 2.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

IL‑28A/IFN‑ lambda 2 Inhibition of EMCV‑induced Cytopathy and Neutralization by Human IL‑28A/IFN‑ lambda 2 Antibody. Recombinant Human IL-28A/IFN-lambda 2 (Catalog # 1587-IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Human IL-28A/IFN-lambda 2 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IL-28A/IFN-lambda 2 Monoclonal Antibody (Catalog # MAB1587). The ND₅₀ is typically 1-8 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-28A/IFN-lambda 2

IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11‑13% aa sequence identity) and type I IFN family (15‑19% aa sequence identity) (1‑3). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and
up‑regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL‑10 receptor beta
(IL‑10 R beta ) and a novel IL‑28 receptor alpha (IL‑28 R alpha, also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory regions of the target genes. Human IL-28A cDNA encodes a 200 amino acid (aa) residue precursor protein with a 25 aa signal peptide. It shares 94% and 67% aa sequence identity with human IL-28B and human IL-29, respectively.

References

Vilcek, J. (2003) Nature Immunol. 4:8.
Sheppard, P. et al. (2003) Nature Immunol. 4:63.
Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.

Long Name

Interleukin 28A

Entrez Gene IDs

282616 (Human)

Alternate Names

interleukin-28A; IFN-lambda 2; IL28A; IL-28A; interferon, lambda 2

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human IL-28A/IFN-lambda 2 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

3 Citations: Showing 1 - 3
Filter your results:

Filter by:

Highly sensitive reporter cell line for detection of interferon types I-III and their neutralization by antibodies
Authors: Groen, K;Kuratli, R;Sar, L;Vasou, A;Huber, M;Hughes, DJ;Hale, BG;
European journal of immunology
Species: Human
Sample Types: Plasma, Recombinant Protein
Applications: Neutralization
Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells.
Authors: Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T, Lewis-Antes A, Amrute S, Garrigues U, Doyle S, Donnelly R, Kotenko S, Fitzgerald-Bocarsly P
J Immunol, 2012-08-13;189(6):2735-45.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer
Authors: J Hong, JH Lee, Z Zhang, Y Wu, M Yang, Y Liao, R de la Rosa, J Scheirer, D Pechacek, N Zhang, Z Xu, T Curiel, X Tan, TH Huang, K Xu
Cancer Research, 2022-12-16;0(0):.